# Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma

> **NCT00807196** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Maisonneuve-Rosemont Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Non-Hodgkins Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** 90Y ibritumomab tiuxetan (Zevalin)
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **OTHER:** Non myeloablative allogeneic stem cell transplantation

## Key facts

- **NCT ID:** NCT00807196
- **Lead sponsor:** Maisonneuve-Rosemont Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-09
- **Primary completion:** 2011-12
- **Final completion:** 2012-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2008-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00807196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00807196, "Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00807196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*